Download the News Release
Nanopharm, an Aptar Pharma company, focused on providing highly specialized OINDP development and analytical services that accelerates the development of your drug-device combination product to reach the market faster, has announced expansion plans to better support increased customer needs.
The new facility in Cwmbran, Wales will create an estimated 60 new employment opportunities and allow Nanopharm to substantially increase its full services capacity, including the expansion of its formulation and analytical capabilities, to facilitate the rapid growth of its business.
The company has signed a long-term lease on a nearby building that is four times larger than its current premises in Newport, Wales. The facility, spanning three floors and 25,000 sq. ft., has been completely redesigned to house state-of-the-art research and development (R&D), and analytical laboratories, with construction expected to be completed in early 2022.
Building on the company’s heritage and belief that fundamental materials science drives behavior in aerosol science, the addition of new characterization and analytical capabilities as well as increased capacity will enable Nanopharm’s scientists to provide specialist services, benefit from in-house evaluation and facilitate the customers’ desire to get to the clinic quickly, yet safely. The new analytical laboratories will also be cGMP compliant to allow Nanopharm to further support its customers through their new product development process.
The new facility will include cGMP testing, biologics characterization, and particle engineering capabilities for orally inhaled and nasal drug products (OINDPs). In-house particle engineering capabilities will be significantly expanded, including the installation of a one-of-a-kind spray dryer with world-class flexibility and scalability to multiple commercial platforms.
